Identifying opportunities to address the congestive heart failure burden: The Improving Cardiovascular Outcomes in Nova Scotia (ICONS) study

Canadian Journal of Cardiology

Volumn 19, Issue 4, 2003, Pages 439-444

  Howlett, Jonathan G ^a   Johnstone, David E ^a   Sketris, Ingrid ^a   O'Reilly, Michael ^b   Horne, Gabrielle S ^a   Cox, Jafna L ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Valley Regional Hospital   (Canada)

Author keywords

Congestive heart failure; Disease burden; Outcomes research; Quality of care

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRATE; WARFARIN;

ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CLINICAL STUDY; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEATH; DRUG USE; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HEALTH CARE; HEALTH CARE FACILITY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; OUTCOMES RESEARCH; PRESCRIPTION; PROSPECTIVE STUDY; SURVIVAL;

AGED; AGED, 80 AND OVER; COST OF ILLNESS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; LENGTH OF STAY; MALE; MEDICAL RECORDS; MIDDLE AGED; NOVA SCOTIA; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT ADMISSION; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 0038290607     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985-95. Am Heart J 1999;137:352-60.
2. Andrews R, Cowley AJ. Clinical and economic factors in the treatment of congestive heart failure. PharmacoEcnomics 1995;7:119-27.
3. McMurray JJV, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: Public and private health burden. Eur Heart J 1998;19(Suppl P):9-16.
4. http://www.gov.ns.ca/finance/xfedprov/freports/9802/fnreport.htm December 20, 2001.
5. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: Rationale for preventive strategies and comprehensive disease management. Am Heart J 1997;133:703-12.
6. Heart and Stroke Foundation of Canada, Health Canada, Statistics Canada. The Changing Face of Heart Disease and Stroke in Canada. Ottawa: Heart and Stroke Foundation of Canada, 1999.
7. Johnstone DE, Abdulla A, Arnold JM, et al. Diagnosis and management of heart failure. Can J Cardiol 1994;10:613-31.
8. Philbin EF. Factors determining angiotensin-converting enzyme inhibitor underutilization in heart failure in a community setting. Clin Cardiol 1998;21:103-8.
9. Montague T, Teo K, Taylor L, McAlister F, Ackman M, Tsuyuki R. In pursuit of optimal care and outcomes for patients with congestive heart failure: Insights from the past decade. In: Dhalla NZ, Zahradka P, Dixon IMC, Beamish RE, eds. Angiotensin II Receptor Blockade. Physiological and Clinical Implications. Boston: Kluwer Academic Publishers, 1997.
10. Cox J on Behalf of the ICONS Investigators. Optimizing disease management at a health care system level: The rationale and methods of the Improving Cardiovascular Outcomes in Nova Scotia (ICONS) Study. Can J Cardiol 1999;15:787-96.
11. Statistics Canada www.statisticscanada.ca, Accessed December 5, 2001.
12. McIntyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in heart failure: Trends in case fatality in 66,547 patients hospitalized between 1986 and 1995. Circulation 2000;102:1126-31.
13. Bellotti P, Badano LP, Acquarone N, et al. Specialty-related differences in the pidemiology, clinical profile, management and outcome of patients hospitalized for heart failure. The OSCUR Study. Eur Heart J 2001;22:596-604.
14. Nohria A, Chen YT, Morton DJ, Walsh R, Vlasses PH, Krumholtz HM. Quality of care for patients hospitalized with heart failure at academic medical centers. Am Heart J 1999;137:1028-34.
15. Philbin EF, Rocco TA, Lindemuth NW, Ulrich K, McCall M, Jenkins PL. The results of a randomized trial of a quality improvement intervention in the care of patients with heart failure. The MISCHF Study. Am J Med 2000;109:443-9.
16. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the cooperative North Scandinavian enalapril survival study (CONSENSUS) Study. N Engl J Med 1987;316:1425-35.
17. Cleland JGF, Khand A, Clark A. The heart failure epidemic: Exactly how big is it? Eur Heart J 2001;22:623-6.
18. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary, intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190-5.
19. Stewart S, Marley JE, Horowitz JD. Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: A randomized controlled study. Lancet 1999;354:1077-83.
20. Kinsella A, Warner I. Telehealth and managing congestive heart failure. Caring 1998;17:14-8.
21. Philbin EF, Dec GW, Jenkins PL, DiSalvo TG. Socioeconomic status as an important risk factor for hospital readmission for heart failure. Am J Cardiol 2001;87:1367-71.
22. Philbin EF, McCullough PA, DiSalvo TG, Dec GW, Jenkins PL, Weaver WD. Socioeconomic status is an important determinant of the use of invasive procedures after acute myocardial infarction in New York State. Circulation 2000;102 (19 Suppl 3):III107-15.
23. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
24. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-300.
25. Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
26. The Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. Increasing awareness and improving the management of heart failure in Europe: The IMPROVEMENT of HF initiative. Eur J Heart Fail 1999;1:139-44.
27. SEOSI Investigators. Survey on heart failure in Italian hospital cardiology units. Results of the SEOSI Study. Eur Heart J 1997;18:1457-64.
28. Cohen-Soial A, Desnos M, Delahaye F, Emeriau JP, Hanania G (for the Myocardiopathy and Heart Failure Working Group of the French Society of Cardiology, the National College of General Hospital Cardiologists and the French Geriatrics Society). A national survey of heart failure in French hospitals. Eur Heart J 2000;21:763-9.
29. Weil E, Tu JV. Quality of congestive heart failure treatment at a Canadian teaching hospital. CMAJ 2001;165:284-7.
30. The Clinical Quality Improvement Network (CQIN) Investigators. Low incidence of assessment and modification of risk for cardiovascular events, particularly among females and the elderly. Am J Cardiol 1995;76:570-3.
31. McDermott MM, Lee P, Mehta S, Gheorghiade M. Patterns of angiotensin-converting enzyme inhibitor prescriptions, educational interventions, and outcomes among hospitalized patients with heart failure. Clin Cardiol 1998;21:261-8.
32. McMurray JJV. Failure to practice evidence-based medicine: Why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors? Eur Heart J 1998;28(Suppl L):L15-21.
33. Ferreira A, Bettencourt P, Cortez M, Arujo JP, Cerqueira-Gomez M. Angiotensin converting enzyme inhibitors in heart failure: Physicians' prescribing behavior. J Card Fail 1997;3:295-302.
34. Edep ME, Sshah NB, Tateo IM, Massie BM. Differences between primary care physicians and cardiologists in the management of congestive heart failure: Relation to practice guidelines. J Am Coll Cardiol 1997;30:518-26.
35. Pitt B, Poole-Wilson PA, Segal R, et al (on behalfofthe ELITE II investigators). Effect of losartan compared with captoril on mortality in patients with symptomatic heart failure: The Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
36. Flather MD, Yusuf S, Kober L. Long term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: A systematic overview of data from individual patients. Lancet 2000;355:1575-81.
37. Swedberg K, Pfeffer M, Granger, Poole-Wilsonl, Rouleau JL. Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. J Card Fail 1999;5:276-82.
38. Cleland JGF, Tendera M, Adamus J, et al (on behalf of the PEP Investigators). Perindopril for elderly people with chronic heart failure: The PEP study. Eur J Heart Fail 1999;1:211-7.